GlassScriptPhysician profile
David L Reinhard
NPI 1003871468
$3,340.19
in general payments reported to CMS, 2019-2025
33 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $410 · 2021: $763 · 2022: $821 · 2023: $489 · 2024: $278 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,204.19 | 2021-2025 | |
| Allergan, INC. | $263.83 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $259.35 | 2019-2024 | Ztlido |
| Amgen INC. | $192.77 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.40 | 2019-2020 | |
| Lundbeck LLC | $138.07 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $98.39 | 2019-2021 | |
| Abbott Laboratories | $97.33 | 2023-2024 | Proclaim, Eterna |
| Boston Scientific Corporation | $95.97 | 2022-2025 | Wavewriter Alpha Prime 16, Intracept |
| Biohaven Pharmaceuticals, INC. | $91.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.00 | 2020-2021 | |
| Pfizer INC. | $83.81 | 2019-2024 | |
| Eisai INC. | $59.09 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $50.26 | 2019-2021 | |
| Bioventus LLC | $41.89 | 2021-2023 | Stimrouter Implantable Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $40.07 | 2021-2022 | |
| Lilly USA, LLC | $35.75 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.28 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $32.84 | 2024 | Rexulti, Nuedexta |
| Ibsa Pharma INC. | $31.25 | 2021-2023 | Tirosint, Licart |
| Arteriocyte Medical Systems, INC. | $27.79 | 2019 | |
| Merz North America, INC. | $27.21 | 2020 | |
| Merz Pharmaceuticals, LLC | $23.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.12 | 2022 | |
| Impel Pharmaceuticals INC. | $21.75 | 2022 | |
| Painteq LLC | $21.54 | 2024 | Painteq |
| Collegium Pharmaceutical, INC. | $20.90 | 2024 | Belbuca |
| Electronic Waveform Lab, INC. | $18.90 | 2019 | |
| Redhill Biopharma INC. | $16.71 | 2021 | |
| Tanabe Pharma America, INC. | $15.97 | 2021 | |
| Sentynl Therapeutics, INC. | $13.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.08 | 2019 | |
| Biodelivery Sciences International, INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reinhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.